{"nctId":"NCT03188185","briefTitle":"A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)","startDateStruct":{"date":"2017-06-12","type":"ACTUAL"},"conditions":["Major Depressive Disorder"],"count":278,"armGroups":[{"label":"ALKS 5461","type":"EXPERIMENTAL","interventionNames":["Drug: ALKS 5461"]},{"label":"ALKS 5461 Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: ALKS 5461 Placebo"]}],"interventions":[{"name":"ALKS 5461","otherNames":[]},{"name":"ALKS 5461 Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a Major Depressive Disorder (MDD) primary diagnosis\n* Have a body mass index (BMI) of 18.0 to \\</= 40.0 kg/m\\^2\n* Be willing and able to follow the study procedures and visits as outlined in the protocol (including agreeing not to enroll in any other clinical trials)\n* Have inadequate responses to antidepressant therapy (ADT) in the current Major Depressive Episode (MDE)\n* Additional criteria may apply\n\nExclusion Criteria:\n\n* Has any finding that would compromise the safety of the subject or affect their ability to adhere to the protocol visit schedule or fulfill visit requirements\n* Has any other significant medical condition (eg, neurological, psychiatric, or metabolic) or clinical symptom that could unduly risk the subject or affect the interpretation of study data\n* Has any current primary diagnosis other than MDD, where primary diagnosis is defined as the primary source of current distress and functional impairment\n* Has experienced hallucinations, delusions, or any psychotic symptoms in the current MDE\n* Has been hospitalized for MDD within 3 months before screening\n* Has used opioid agonists (eg, codeine, oxycodone, tramadol, morphine) or opioid antagonists (eg, naloxone, naltrexone) within 14 days prior to screening\n* Has received electroconvulsive therapy treatment within the last 2 years or within the current MDE or failed a course of electroconvulsive treatment at any time\n* Has a significant risk for suicide\n* Has a positive breath alcohol test at screening\n* Has a positive test for drugs of abuse at screening or visit 2\n* Is pregnant, planning to become pregnant, or is breastfeeding during the study\n* Additional criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to the End of Treatment (EOT) in the Montgomery Asberg Depression Rating Scale-10 (MADRS-10) Scores","description":"The MADRS-10 scale is a clinician-administered questionnaire comprised of 10 items used to measure the severity of Major Depressive Disorder (MDD) symptoms. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms). Individual questionnaire items include: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.4","spread":"0.70"},{"groupId":"OG001","value":"-13.9","spread":"1.12"},{"groupId":"OG002","value":"-4.2","spread":"1.06"},{"groupId":"OG003","value":"-4.7","spread":"1.11"}]}]}]},{"type":"SECONDARY","title":"Montgomery Asberg Depression Rating Scale (MADRS) Response Rate","description":"The percentage of subjects demonstrating a MADRS-10 treatment response, defined as a \\>/= 50% reduction in MADRS-10 score from baseline to the end of the efficacy period (Week 5 for Stage 1, Week 6 for Stage 2). The MADRS-10 scale is a measure of the severity of Major Depressive Disorder (MDD) symptoms and includes the following 10 items: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"49","spread":null},{"groupId":"OG002","value":"54","spread":null},{"groupId":"OG003","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Montgomery Asberg Depression Rating Scale (MADRS) Remission Rate","description":"The percentage of subjects achieving remission, defined as a subject with a score \\</= 10 at the end of the efficacy period (Week 5 for Stage 1, Week 6 for Stage 2). The MADRS-10 scale is a measure of the severity of Major Depressive Disorder (MDD) symptoms and includes the following 10 items: Apparent Sadness, Reported Sadness, Inner Tension, Reduced Sleep, Reduced Appetite, Concentration Difficulties, Lassitude, Inability to Feel, Pessimistic Thoughts, and Suicidal Thoughts. Scores range from 0 (no apparent symptoms) to 60 (most severe symptoms).the end of the efficacy period.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"164","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"54","spread":null},{"groupId":"OG003","value":"55","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":198},"commonTop":["Nausea","Dizziness","Headache","Somnolence","Sedation"]}}}